General Announcement::Initiate Clinical Study for GBR 1342, Second Investigational New Drug from Immuno-Oncology Portfolio

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
16-May-2017 12:43:28
Status
New
Announcement Sub Title
Initiate Clinical Study for GBR 1342, Second Investigational New Drug from Immuno-Oncology Portfolio
Announcement Reference
SG170516OTHRFS0B
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
16/05/2017 17:00:00
Description (Please provide a detailed description of the event in the box below)
Sub:- Glenmark Pharmaceuticals to Initiate Clinical Study for GBR 1342, Second Investigational New Drug from Immuno-Oncology Portfolio

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Attachments

SGX 16.05.2017.pdf
Total size =876K